| Drug Name |
Clofazimine |
| Drug ID |
BADD_D00496 |
| Description |
Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids.[A203144] Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis treatments such as [rifampicin] and [isoniazid].[A203144] |
| Indications and Usage |
Clofazimine is indicated for the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.[L13802] To prevent the development of drug resistance, it should be used only in combination with other antimycobacterial leprosy treatments. |
| Marketing Status |
approved; investigational |
| ATC Code |
J04BA01 |
| DrugBank ID |
DB00845
|
| KEGG ID |
D00278
|
| MeSH ID |
D002991
|
| PubChem ID |
2794
|
| TTD Drug ID |
D0S5UH
|
| NDC Product Code |
59349-0030; 46016-2030 |
| UNII |
D959AE5USF
|
| Synonyms |
Clofazimine | N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-((1-methylethyl)imino)-2-phenazinamine | Lamprene | B-663 | B 663 | B663 | G-30,320 | G 30,320 | G30,320 |
